PDF(Pubmed)
Abstract：
Molecular medicine opened new horizons in understanding disease mechanisms and discovering target interventions. The wider availability of DNA and RNA sequencing, immunohistochemical analysis, proteomics, and other molecular tests changed how physicians manage diseases. The gastric cancer molecular classification proposed by The Cancer Genome Atlas Program divides gastric adenocarcinomas into four subtypes. However, the available targets and/or immunotherapies approved for clinical use seem to be dissociated from these molecular subtypes. Until a more reliable interpretation of the stupendous amount of data provided by the molecular classifications is presented, the clinical guidelines will rely on available actionable targets and approved therapies to guide clinicians in conducting cancer management in the era of molecular therapies.
摘要：
分子医学在理解疾病机制和发现目标干预措施方面开辟了新的视野。更广泛的DNA和RNA测序，免疫组织化学分析,蛋白质组学，和其他分子测试改变了医生管理疾病的方式。癌症基因组图谱计划提出的胃癌分子分类将胃腺癌分为四种亚型。然而,批准临床使用的可用靶标和/或免疫疗法似乎与这些分子亚型分离。直到对分子分类提供的大量数据进行更可靠的解释，在分子治疗时代,临床指南将依靠可用的可操作靶点和已批准的治疗方法来指导临床医生进行癌症治疗.
